Laurence Albiges

Laurence Albiges

MD, PhD

Gustave Roussy, Paris, France

Biomarker development in RCC and UC

Biomarker development in RCC and UC

Laurence Albiges • 23 Sep 2021

Current and emerging treatment strategies for patients with mccRCC

Current and emerging treatment strategies for patients with mccRCC

Laurence Albiges • 23 Sep 2021

BIONIKK: the first trial study in mccRCC

BIONIKK: the first trial study in mccRCC

Laurence Albiges • 18 Sep 2020

Treating patients with RCC in 2020 and beyond

Treating patients with RCC in 2020 and beyond

Laurence Albiges • 18 Sep 2020

RCC data at ESMO 2020

RCC data at ESMO 2020

Laurence Albiges • 18 Sep 2020

CheckMate 214 trial update

CheckMate 214 trial update

Laurence Albiges • 18 Sep 2020

Unmet needs in RCC

Unmet needs in RCC

Laurence Albiges • 22 May 2020

RCC: challenging clinical scenarios

Laurence Albiges

Nivolumab for nccRCC

Laurence Albiges

CaboPoint: second-line cabozantinib for RCC

Laurence Albiges

Updates on JAVELIN renal 101: primary treatment for patients

Updates on JAVELIN renal 101: primary treatment for patients

Laurence Albiges • 1 Oct 2019

NIVOREN GETUG-AFU 26: Updates and implications

NIVOREN GETUG-AFU 26: Updates and implications

Laurence Albiges • 1 Oct 2019

First-line treatment guidelines: combination strategy

First-line treatment guidelines: combination strategy

Laurence Albiges

Access limitations: the key challenges facing RCC treatment in France

Access limitations: the key challenges facing RCC treatment in France

Laurence Albiges • 15 Feb 2019

Targeted therapies for the treatment of mRCC after nivolumab-ipilimumab failure

Targeted therapies for the treatment of mRCC after nivolumab-ipilimumab failure

Laurence Albiges • 15 Feb 2019

Safety and efficacy of nivolumab in mRCC: Final analysis from the NIVOREN study

Safety and efficacy of nivolumab in mRCC: Final analysis from the NIVOREN study

Laurence Albiges • 15 Feb 2019

1
2
Next